Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $608.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $608.4 million, up 91.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 68.37% YoY), and the FY2025 annual result was $563.8 million, up 70.36% from the prior year.
• Liabilities and Shareholders Equity climbed to $608.4 million in Q1 2026 per SLNO's latest filing, from $563.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $608.4 million in Q1 2026 and troughed at $19.5 million in Q1 2023.
• A 5-year average of $232.7 million and a median of $180.7 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity slumped 54.08% in 2023, then soared 882.84% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $26.5 million in 2022, then soared by 581.93% to $180.7 million in 2023, then surged by 83.17% to $331.0 million in 2024, then soared by 70.36% to $563.8 million in 2025, then gained by 7.9% to $608.4 million in 2026.
• Business Quant data shows SLNO's Liabilities and Shareholders Equity at $608.4 million in Q1 2026, $563.8 million in Q4 2025, and $599.9 million in Q3 2025.